By Dr Jamie Fletcher

Preprints

Maris J; Soria-Bretones I; Casás-Selves M; Samanta M; Groff D; Murray J; Fletcher J; Farrel A; Pastor S; Patel K; Goodfellow EG; Li L; Caron C; Shiwram A; Kim H; Henry D; Laterreur N; Bowlan J; Krytska K; Neuhauser S; Stearns T; Schubert J; Wu J; Surrey L; Álvarez-Quilón A; Vallée F; Nejad P; Schonhoft J; Li J; Veloso A; Young J; Hyer M; Morris S; Mossé YP; Marshall G; Haber M; Zimmermann M, 2025, The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity., http://dx.doi.org/10.21203/rs.3.rs-7014295/v1

Han JZR; Phimmachanh M; Hastings J; Leong KH; Ng B; Ni J; Fontaine-Titley A; Cadell A; O’Donnell YEI; Clearwater M; Kamili A; Haber M; Norris M; Timpson P; Trahair T; Fletcher J; Fey D; Kolch W; Latham S; Croucher D, 2025, Inclusion of JNK-independent drugs within multi-agent chemotherapy improves response in relapsed high-risk neuroblastoma, http://dx.doi.org/10.1101/2025.04.26.650760

Jung M; Poltavets V; Skhinas J; Tax G; Kamili A; Xie AJ; Ghamrawi S; Graber P; Mao J; Wong-Erasmus M; Cui L; Kimpton K; Venkat P; Mayoh C; Fleuren E; Fordham A; Barger Z; Grady J; Thomas D; Du EY; Cowley M; Gifford A; Fletcher J; Lau L; Dolman E; Gooding J; Kavallaris M, 2024, Engineered paediatric tumours retain maintains tumour genotype and phenotype for precision medicine, http://dx.doi.org/10.1101/2024.11.17.619539

Nelson C; Rogers S; Roychoudhury K; Tan YS; Atkinson C; Sobinoff A; Tomlinson C; Hsu A; Lu R; Dray E; Haber M; Fletcher J; Cesare A; Hegde R; Pickett H, 2022, The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation, http://dx.doi.org/10.1101/2022.10.10.511510

Back to profile page